Kolkata, West Bengal -- (SBWIRE) -- 09/23/2013 -- Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on Orexigen Therapeutics, Inc. (NASDAQ:OREX), Baidu.com, Inc. (ADR)(NASDAQ:BIDU), VIVUS, Inc.(NASDAQ:VVUS).
Orexigen Therapeutics, Inc. (NASDAQ:OREX) shares dropped 2.31% and closed at $6.55 in the last trading session. The company announced that management was scheduled to present a company overview at the Bank of America Merrill Lynch Global Healthcare Conference in London. The presentation is scheduled for Thursday, September 12(th) at 9:30 a.m. London Time.
Additionally, the company on August 27 announced that the Light Study independent Data Monitoring Committee has recently confirmed that sufficient major adverse cardiovascular events (MACE) are expected to occur within the next two months, enabling the interim analysis to be conducted by early December and the potential resubmission of the Contrave® New Drug Application (NDA) by year end.
Should Investors Buy OREX After Yesterday’s Jump? Find Out Here
Baidu.com, Inc. (ADR)(NASDAQ:BIDU) shares declined 0.98% to $146.25. Baidu Inc. (BIDU)’s travel-booking service Qunar.com Inc. is planning a U.S. initial public offering that may raise about $150 million, said two people with knowledge of the matter on Sept. 9.
Qunar, which runs China’s most popular mobile travel app, is working with Deutsche Bank AG and Goldman Sachs Group Inc. on the sale, said the people, who asked not to be identified because the process is private. An IPO may take place as early as in the fourth quarter, they said. Baidu, operator of China’s largest search engine, paid $306 million in 2011 for a majority stake in Qunar to tap the country’s growing travel market.
Is BIDU A Good Buy After The Recent Price Movement? Find Out Here
VIVUS, Inc.(NASDAQ:VVUS) shares declined 1.16% to $10.25. The company on Sept. 20 announced it has submitted to the European Medicines Agency (EMA) a request for scientific advice regarding use of a pre-specified interim analysis from the AQCLAIM cardiovascular outcomes trial (CVOT) to support the resubmission of the marketing authorization application (MAA) for approval in Europe of Qsiva™ for obesity under the centralized procedure. In order to accommodate advice from the European authorities, VIVUS anticipates that patient enrollment for the AQCLAIM study will commence in first quarter 2014.
Additionally, the company on Sept. 4 said new Chief Executive Officer Tony Zook has resigned because of health reasons. Seth H. Z. Fischer, formerly with Johnson & Johnson (JNJ), will replace Zook immediately, the Mountain View, California-based company said in a statement.
Is VVUS A Good Buy After The Recent Price Movement? Find Out Here
Specialpennystockalert.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Specialpennystockalert.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
The assembled information disseminated by Specialpennystockalert.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Specialpennystockalert.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)